Acadia Q1: Slight improvement but fails to boost investment outlook

Juanmonino/E+ via Getty Images


Acadia Pharmaceuticals (NASDAQ: ACAD) is a commercial-stage biotechnology company that specializes in developing treatments for diseases of the central nervous system. Among the FDA-approved products is Nuplazid (pimavanserin), which is used to manage hallucinations and delusions associated with the psychosis of Parkinson’s disease (PDP). Another product in

Leave a Comment

Your email address will not be published. Required fields are marked *